Answers are grounded in this paper and cite their sources.
This review will give a brief overview of the pharmacology of the melanocortin receptors (MCRs) as a background. The review will not handle the patents or patent applications dealing with cloning of the different subtypes of the receptor, since this has been recently reviewed [1]. This review will focus on different ligands acting either as agonists or antagonists to the different subtypes of the receptor, i.e., MC1R, MC3R, MC4R and MC5R. Just recently a number of patent applications have reached the public domain, which describe small peptides or low molecular weight organic compounds binding and acting on the MCRs.
No takes yet. Share an insight, caveat, or question.
Andersson et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: